Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies

NCT07214688 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT07214688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies
Lead sponsor
Hackensack Meridian Health
Phase
Phase 2
Overall status
Recruiting
Start date
January 6, 2026
Completion date
January 31, 2032
Enrollment
209 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplant recipient